Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Anai

Showing results (101-110 of 175) with videos related to

Pageof 18
Sort By:
Molecular Cancer Therapeutics|July 23, 2008
Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiationAtsushi Tomioka, Motoyoshi Tanaka, Marco A De Velasco, et al.
Clinical Case Reports|January 5, 2024
Early diagnosis of thoracic spinal dural arteriovenous fistula using lumbar magnetic resonance imaging: A case reportMay Pyae Kyaw, Tatsuya Tanaka, Satoshi Anai, et al.
Theranostics|February 28, 2019
Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral GrowthMakito Miyake, Hideki Furuya, Sayuri Onishi, et al.
Diagnostics (Basel, Switzerland)|March 18, 2020
Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell CarcinomaTakuto Shimizu, Makito Miyake, Shunta Hori, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 11, 2021
Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidilFumisato Maesaka, Nobumichi Tanaka, Yasushi Nakai, et al.
Anticancer Research|July 24, 2010
Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cellsMakito Miyake, Kiyohide Fujimoto, Satoshi Anai, et al.
Contemporary Clinical Trials Communications|July 18, 2019
Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label studyYoshifumi Kadono, Hiroyuki Konaka, Kouji Izumi, et al.
Japanese Journal of Clinical Oncology|October 31, 2019
Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosteroneYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Oncology Reports|January 6, 2011
Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladderMakito Miyake, Kiyohide Fujimoto, Satoshi Anai, et al.
Urology|January 29, 2013
Phosphorylation status of Fas-associated death domain protein is associated with biochemical recurrence after radical prostatectomyTomohiro Ikeda, Nobumichi Tanaka, Keiji Shimada, et al.
Pageof 18

Showing results (101-110 of 175) with videos related to

Sort By:
Pageof 18
Molecular Cancer Therapeutics|July 23, 2008
Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiationAtsushi Tomioka, Motoyoshi Tanaka, Marco A De Velasco, et al.
Clinical Case Reports|January 5, 2024
Early diagnosis of thoracic spinal dural arteriovenous fistula using lumbar magnetic resonance imaging: A case reportMay Pyae Kyaw, Tatsuya Tanaka, Satoshi Anai, et al.
Theranostics|February 28, 2019
Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral GrowthMakito Miyake, Hideki Furuya, Sayuri Onishi, et al.
Diagnostics (Basel, Switzerland)|March 18, 2020
Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell CarcinomaTakuto Shimizu, Makito Miyake, Shunta Hori, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 11, 2021
Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidilFumisato Maesaka, Nobumichi Tanaka, Yasushi Nakai, et al.
Anticancer Research|July 24, 2010
Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cellsMakito Miyake, Kiyohide Fujimoto, Satoshi Anai, et al.
Contemporary Clinical Trials Communications|July 18, 2019
Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label studyYoshifumi Kadono, Hiroyuki Konaka, Kouji Izumi, et al.
Japanese Journal of Clinical Oncology|October 31, 2019
Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosteroneYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Oncology Reports|January 6, 2011
Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladderMakito Miyake, Kiyohide Fujimoto, Satoshi Anai, et al.
Urology|January 29, 2013
Phosphorylation status of Fas-associated death domain protein is associated with biochemical recurrence after radical prostatectomyTomohiro Ikeda, Nobumichi Tanaka, Keiji Shimada, et al.
Pageof 18